JP2016526574A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526574A5
JP2016526574A5 JP2016525817A JP2016525817A JP2016526574A5 JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5 JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
nhs
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525817A
Other languages
English (en)
Japanese (ja)
Other versions
JP6739333B2 (ja
JP2016526574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046409 external-priority patent/WO2015006728A2/en
Publication of JP2016526574A publication Critical patent/JP2016526574A/ja
Publication of JP2016526574A5 publication Critical patent/JP2016526574A5/ja
Application granted granted Critical
Publication of JP6739333B2 publication Critical patent/JP6739333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525817A 2013-07-11 2014-07-11 部位特異的化学酵素的タンパク質修飾 Active JP6739333B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361845273P 2013-07-11 2013-07-11
US61/845,273 2013-07-11
US201462016044P 2014-06-23 2014-06-23
US62/016,044 2014-06-23
PCT/US2014/046409 WO2015006728A2 (en) 2013-07-11 2014-07-11 Site-specific chemoenzymatic protein modifications

Publications (3)

Publication Number Publication Date
JP2016526574A JP2016526574A (ja) 2016-09-05
JP2016526574A5 true JP2016526574A5 (cg-RX-API-DMAC7.html) 2017-08-24
JP6739333B2 JP6739333B2 (ja) 2020-08-12

Family

ID=51298955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525817A Active JP6739333B2 (ja) 2013-07-11 2014-07-11 部位特異的化学酵素的タンパク質修飾

Country Status (12)

Country Link
US (4) US9359400B2 (cg-RX-API-DMAC7.html)
EP (2) EP3019515B1 (cg-RX-API-DMAC7.html)
JP (1) JP6739333B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160040556A (cg-RX-API-DMAC7.html)
CN (1) CN105593238B (cg-RX-API-DMAC7.html)
AU (1) AU2014286990A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016000585A2 (cg-RX-API-DMAC7.html)
CA (1) CA2918076A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690205A1 (cg-RX-API-DMAC7.html)
ES (1) ES2756526T3 (cg-RX-API-DMAC7.html)
MX (1) MX2016000393A (cg-RX-API-DMAC7.html)
WO (1) WO2015006728A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359400B2 (en) 2013-07-11 2016-06-07 Novartis Ag Site-specific chemoenzymatic protein modifications
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MY192987A (en) * 2015-12-18 2022-09-20 Eisai R&D Man Co Ltd C-terminal lysine conjugated immunoglobulins
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
PE20190340A1 (es) 2016-06-10 2019-03-07 Eisai Randd Man Co Ltd Inmunglobulinas conjugadas con lisina
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
AU2020212055B2 (en) * 2019-01-25 2025-10-02 Avedro, Inc. Bis(diazirine) derivatives as photo-crossslinker for treating corneal ectatic disorders
JP2025520445A (ja) * 2022-06-16 2025-07-03 ザ ジェネラル ホスピタル コーポレイション 細胞イメージング用のビシクロノニン試薬
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE4022267C2 (de) * 1990-07-12 1994-09-15 Degussa N-Acyldipeptide und deren Verwendung
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
ES2171418T3 (es) 1992-08-31 2002-09-16 Baxter Healthcare Sa Vacunas contra neisseria meningitidis del grupo c.
US5508191A (en) 1993-07-05 1996-04-16 Takeda Chemical Industries, Ltd. Mutant strains of agrobacterium for producing β-1,3-glucan
ES2267103T3 (es) 1994-08-26 2007-03-01 Novozymes A/S Transglutaminasas microbianas, su produccion y uso.
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
NZ298746A (en) 1995-01-19 1998-07-28 Novo Nordisk As Transglutaminases from oomcyetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
EP0815833B1 (en) * 1996-06-24 2003-04-09 Givaudan SA Malodour preventing agents
WO1998013381A1 (fr) 1996-09-26 1998-04-02 Ajinomoto Co., Inc. Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
JP3981525B2 (ja) 1998-01-20 2007-09-26 ハワード・グリーン 組織への物質のトランスグルタミナーゼ連結
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP2332581B1 (en) 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2006028129A1 (ja) 2004-09-10 2006-03-16 Toray Industries, Inc. 医薬品製剤
AU2005302269B2 (en) 2004-11-01 2011-05-19 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
TW200716179A (en) * 2005-06-15 2007-05-01 Novo Nordisk As Transglutaminase mediated conjugation of growth hormone
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101809032A (zh) * 2007-08-24 2010-08-18 诺沃-诺迪斯克有限公司 用于选择性修饰蛋白质的方法
US8426179B2 (en) * 2007-08-30 2013-04-23 Northwestern University Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme
DE102007044296A1 (de) * 2007-09-17 2009-03-19 Hans-Lothar Prof. Dr. Fuchsbauer Strukturmodulator von Proteinen
US8137925B2 (en) * 2007-11-09 2012-03-20 Massachusetts Institute Of Technology Methods and compositions for protein labeling using lipoic acid ligases
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JPWO2010002042A1 (ja) 2008-07-04 2011-12-22 国立大学法人九州大学 タンパク質ラベル化用酵素基質
CN102333788A (zh) * 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
WO2011002852A2 (en) 2009-06-30 2011-01-06 The Regents Of The University Of Michigan Pro-drug complexes and related methods of use
US20110020837A1 (en) 2009-07-07 2011-01-27 Universiteit Utrecht Holding B.V. Method for isolating or identifying a target protein interacting with a lipid in a cell
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
ES2527536T7 (es) 2010-04-27 2016-03-08 Synaffix B.V. Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590989A2 (en) 2010-07-09 2013-05-15 Universite de Bretagne Occidentale Modular construction of lipophospholipids
EP2633062B1 (en) 2010-10-29 2017-12-27 Life Technologies Corporation Biotin derivatives
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
CA2814953A1 (en) 2010-12-13 2012-06-21 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
FR2981352B1 (fr) 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
JP2015505824A (ja) 2011-12-01 2015-02-26 アンジオケム インコーポレーテッド 標的化リソソーム酵素化合物
JP5509440B2 (ja) * 2012-06-22 2014-06-04 国立大学法人九州大学 タンパク質−核酸複合体の製造方法および標的物の検出方法
CN105517577A (zh) * 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
US9359400B2 (en) * 2013-07-11 2016-06-07 Novartis Ag Site-specific chemoenzymatic protein modifications

Similar Documents

Publication Publication Date Title
JP2016526574A5 (cg-RX-API-DMAC7.html)
JP2016153410A5 (cg-RX-API-DMAC7.html)
JP2013510120A5 (cg-RX-API-DMAC7.html)
JP2010527913A5 (cg-RX-API-DMAC7.html)
CY1118621T1 (el) Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2012518029A5 (cg-RX-API-DMAC7.html)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2012017342A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
EP4541378A3 (en) Compounds for positron emission tomography
AR099134A1 (es) Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
JP2016130266A5 (cg-RX-API-DMAC7.html)
CU24461B1 (es) Compuestos útiles para tratar envejecimiento prematuro y en particular progeria
JP2016515561A5 (cg-RX-API-DMAC7.html)
JP2012513416A5 (cg-RX-API-DMAC7.html)
JP2018531987A5 (cg-RX-API-DMAC7.html)
AR070352A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto.
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2011137045A5 (cg-RX-API-DMAC7.html)
JP2013514329A5 (cg-RX-API-DMAC7.html)
JP2017531013A5 (cg-RX-API-DMAC7.html)
JP2016516074A5 (cg-RX-API-DMAC7.html)
JP2015528463A5 (cg-RX-API-DMAC7.html)